...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in lipidology >What have we learnt from the clinical outcomes trials with the cetrapibs?
【24h】

What have we learnt from the clinical outcomes trials with the cetrapibs?

机译：我们从Cetrapibs临床结果试验中学到了什么？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose of reviewThe current review considers what we have learnt from the clinical outcome trials with the cetrapibs; the inhibitors of cholesteryl ester transfer protein that increase HDL cholesterol levels; torcetrapib, dalcetrapib, evacetrapib and anacetrapib.Recent findingsAlthough an off-target increase in blood pressure may have contributed to the failure of torcetrapib in Investigation of Lipid Level Management to Understand its Impact in Atherosclerotics Events, recent evidence shows that torcetrapib also increased atherogenic apoproteins, and this may have contributed to its failure. Evacetrapib and anacetrapib also increase atherogenic apoproteins. This may have contributed to lack of effect of evacetrapib in Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes. The success of anacetrapib in Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification is more likely to have been due to lowering LDL cholesterol than to increasing HDL cholesterol. The lack of potency in increasing HDL cholesterol was initially considered as a reason for the failure of dalcetrapib in dal-OUTCOMES, but recent genomic studies suggest that dalcetrapib may be effective in subjects with a particular genotype, and this is being clinically tested.SummaryCollectively, these clinical outcome trials do not support raising HDL cholesterol by inhibiting cholesteryl ester transfer protein, as a mechanism for improving cardiovascular outcomes, in the total population of subjects with coronary artery disease.
机译：审查目的目前考虑了我们从与CetRaps的临床结果试验中学到的内容;增加HDL胆固醇水平的胆汁甾醇酯转移蛋白的抑制剂; Torcetrapib，dalcetrapib，evacetrapib和anacetrapib。虽然血压的偏离目标增加可能导致Torcetrapib在调查脂质水平管理中的失败，以了解其在动脉粥样晶体学事件中的影响，但最近的证据表明Torcetrapib也增加了血液发生增加的血液植物诱导症，这可能导致其失败。 evacetrapib和anacetrapib也增加了弱血液诱导的凋亡。这可能导致evacetrapib在评估胆能酯转移蛋白质抑制与血管成果的高风险的患者中对胆甾醇酯转移蛋白抑制的临床影响的影响。 Anacetrapib在随机评估中通过脂质改性的随机评估的成功更可能是由于降低LDL胆固醇而不是增加HDL胆固醇。增加HDL胆固醇缺乏效力最初被认为是Dalcetrapib在DAL-结果中失败的原因，但最近的基因组研究表明，Dalcetrapib可以在具有特定基因型的受试者中有效，并且这是在临床上进行的。校长，这些临床结果试验不支持通过抑制胆固醇酯转移蛋白作为改善心血管结果的机制，以抑制胆囊酯转移蛋白，以冠状动脉疾病的总群体中提高心血管结果的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号